Endocrinology
RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death.
22 Jul, 2021 | 11:08h | UTCCommentary: Dapagliflozin in patients with COVID-19: truth or dare – The Lancet Diabetes & Endocrinology
Case report: Treatment-induced neuropathy of diabetes related to abrupt glycemic control.
21 Jul, 2021 | 10:33h | UTC
Commentaries on Twitter
Rapid correction of glycemic control can lead to nerve pain, retinal damage and microalbuminuria, as seen in this clinical case of a patient recently diagnosed with type 1 diabetes: https://t.co/yeUzqpUObT (earn CPD credits)#T1D #DiabetesCare #FOAMed @DrEmilyMcD @McGill_DOM pic.twitter.com/6eTPamtTe0
— CMAJ (@CMAJ) July 20, 2021
Read about our case of Treatment-induced neuropathy of diabetes from abrupt glycemic control in @CMAJ
Rapid ↘️ of HgBa1c caused ↗️ complications (nerves/kidneys/👁/gastroparesis) and takes 🕒 to improve
🙏 to our pt for allowing us to publish https://t.co/9qsJCo8CSB
— Emily McDonald (@DrEmilyMcD) July 20, 2021
UK National Food Strategy: Tax sugar and salt and prescribe veg, report says.
21 Jul, 2021 | 10:30h | UTCNational Food Strategy: Tax sugar and salt and prescribe veg, report says – BBC
Report: National Food Strategy Independent Review
Related: Fiscal policies for diet and the prevention of noncommunicable diseases – World Health Organization (free) AND The Lancet taskforce on NCDs and economics (free series and commentaries) To improve global health, tax the things that are killing us – Financial Times (free policies, articles and commentaries) AND Reducing cardiovascular disease burden through targeted dietary policies (free study and commentaries) AND Fiscal policies for the prevention of diseases (free study and commentary) AND The potential impact of food taxes and subsidies on cardiovascular disease and diabetes burden and disparities (free)
RCT: Once weekly semaglutide 2.0 mg vs. 1.0 mg in patients with type 2 diabetes – Mean change in HbA1c from baseline was −2.2 percentage points with 2.0 mg vs. −1.9 percentage points with 1.0 mg; mean change in bodyweight from baseline was −6.9 kg with 2.0 mg vs. −6.0 kg with 1.0 mg.
20 Jul, 2021 | 10:09h | UTCEfficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial – The Lancet Endocrinology & Diabetes (link to abstract – $ for full-text)
M-A: benefit-to-harm balance of statins in primary prevention of cardiovascular disease generally favorable.
18 Jul, 2021 | 23:16h | UTCNews release: New study suggests benefit-to-harm balance of statins for healthy adults ‘generally favorable’ – BMJ
Commentary on Twitter
Statins are associated with a small increased risk of side effects in patients without a history of heart disease, but these effects are mild compared with the potential benefits of treatment in preventing major cardiovascular events, say researchers https://t.co/Yvn7Ojtx2F
— The BMJ (@bmj_latest) July 17, 2021
Review: Glucocorticoid induced adrenal insufficiency.
18 Jul, 2021 | 23:15h | UTCGlucocorticoid induced adrenal insufficiency – The BMJ
Commentary on Twitter
◾ What factors affect the risk of Glucocorticoid induced adrenal insufficiency?
◾ What regimen can be used for glucocorticoid taper?
◾ How can adrenal function recovery be best assessed?Read our latest clinical review to find out: https://t.co/m814c1rgIs
— The BMJ (@bmj_latest) July 13, 2021
Body-mass index and diabetes risk in 57 low-income and middle-income countries – “Optimal BMI thresholds for diabetes screening ranged from 23·8 kg/m2 among men in east, south, and southeast Asia to 28·3 kg/m2 among women in the Middle East and north Africa and in Latin America and the Caribbean”.
18 Jul, 2021 | 23:10h | UTCBody-mass index and diabetes risk in 57 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 685 616 adults – The Lancet (link to abstract – $ for full-text)
Related: Study shows BMI cut-offs for obesity and diabetes risk do not work for non-white populations. AND Study: Certain Racial/Ethnic Groups More Likely to Have Diabetes and Prediabetes at Lower Weights
Cohort study: Increased risk of long-term risk of anemia after bariatric surgery – Compared with the control group, the incidence of anemia was higher in the gastric bypass group (HR 5.05), the vertical-banded gastroplasty group (HR 2.67), and the gastric banding group (HR 2.76).
15 Jul, 2021 | 09:10h | UTCLong-term risk of anaemia after bariatric surgery: results from the Swedish Obese Subjects study – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Summary: SGLT2 inhibitors and GLP-1 receptor agonists established and emerging indications.
14 Jul, 2021 | 10:56h | UTCSGLT2 Inhibitors and GLP-1 Receptor Agonists: Indications – American College of Cardiology
Original review: SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications – The Lancet (link to abstract – $ for full-text)
AHA Scientific Statement: Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse.
12 Jul, 2021 | 01:43h | UTCNews release: Discrimination, stress linked to poorer heart health in transgender, gender diverse adults – American Heart Association
Review: Lipoprotein(a) and cardiovascular diseases.
12 Jul, 2021 | 01:33h | UTCLipoprotein(a) and Cardiovascular Diseases – JAMA (free for a limited period)
ADA Draft Consensus Report: Management of Type 1 Diabetes in Adults.
8 Jul, 2021 | 09:04h | UTCThe Management of Type 1 Diabetes in Adults — A Consensus Report by the ADA and EASD
Commentaries: ADA/EASD Draft Guidance Aims to Bring Adults With Type 1 Diabetes Out of Shadows – Medscape (free registration required) AND New consensus report on adults with type 1 diabetes focuses on individualised care – Diabetes Times
Related: Guideline: ADA 2021 Standards of Medical Care in Diabetes
Review: Dietary recommendations for prevention of atherosclerosis.
8 Jul, 2021 | 09:03h | UTCDietary recommendations for prevention of atherosclerosis – Cardiovascular Research
News Release: What should I eat to avoid heart disease? – European Society of Cardiology
Commentary: Plant-Based Diet Best for Your Heart – HealthDay
RCT: Cardiovascular and renal outcomes with Efpeglenatide (a GLP-1 receptor agonist) in Type 2 Diabetes.
7 Jul, 2021 | 08:45h | UTC
WHO launches List of Priority Medical Devices for management of cardiovascular diseases and diabetes.
6 Jul, 2021 | 10:09h | UTC
Commentary on Twitter
🆕 WHO List of Priority Medical Devices for management of cardiovascular diseases and diabetes https://t.co/rBkrvwmzuO pic.twitter.com/uvZtrOSiWt
— World Health Organization (WHO) (@WHO) July 5, 2021
M-A: SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure.
30 Jun, 2021 | 10:08h | UTC
RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.
28 Jun, 2021 | 09:46h | UTC
RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.
28 Jun, 2021 | 09:45h | UTCTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Combo GIP/GLP-1 Drug Superior for HbA1c Reduction in T2D – MedPage Today (free registration required)
Guideline | Perimenopause and Postmenopause – Diagnosis and Interventions.
28 Jun, 2021 | 09:32h | UTC
Perspective | Why are people with obesity more vulnerable to COVID?
25 Jun, 2021 | 10:21h | UTCWhy Are People with Obesity More Vulnerable to COVID? – Scientific American
Viewpoint | Progress in Pharmacotherapy for Obesity.
24 Jun, 2021 | 09:46h | UTCProgress in Pharmacotherapy for Obesity – JAMA (free for a limited period)
See also: Semaglutide’s Success Could Usher in a “New Dawn” for Obesity Treatment – JAMA (free for a limited period)
Audio clinical review: Semaglutide for Weight Loss
Cohort study: no association was found between statin therapy and cognitive decline or incident dementia in older adults.
23 Jun, 2021 | 10:14h | UTCCommentaries: Statin Therapy Not Associated With Cognitive Decline, Dementia in Older Adults, Study Says – American College of Cardiology AND Effect of Statins on Cognitive Decline and Dementia in Older Adults – American College of Cardiology
Expert analysis | The global prevention of cardiovascular disease among people living with diabetes: leading with heart.
23 Jun, 2021 | 10:13h | UTCOriginal publication and resources: The Global Diabetes Compact – World Health Organization
See also: The WHO Global Diabetes Compact: a new initiative to support people living with diabetes – The Lancet Diabetes & Endocrinology (free registration required)
Study shows overuse of levothyroxine in patients with subclinical hypothyroidism despite evidence of no benefit.
22 Jun, 2021 | 09:57h | UTCLevothyroxine Use in the United States, 2008-2018 (free for a limited period)
Editorial: Overuse of Levothyroxine in Patients With Subclinical Hypothyroidism: Time to “Leve”-Out-Thyroxine – JAMA Internal Medicine (free for a limited period)
Related: RCT: Levothyroxine does not reduce the risk of developing depressive symptoms in older adults with subclinical hypothyroidism (studies and guidelines on the subject)
Expert analysis: the ever-growing role of coronary artery calcium in primary prevention.
22 Jun, 2021 | 09:54h | UTC
Commentary on Twitter
New ACC Expert Analysis: The Ever-Growing Role of Coronary Artery Calcium in Primary Prevention.
More: https://t.co/GSsEqkoMbi @miguelcainzos23 @rblument1 @AndyGagel #ASCVD #cvPrev pic.twitter.com/7cUOAIArz9
— American College of Cardiology (@ACCinTouch) June 22, 2021